RACING TO CURE

ALZHEIMER'S & PARKINSON'S

Biomarker Testing Is Step One

Research supported by:

NIH
MJFoxHeader-Logo-1
McGovern-Logo-1
ADDF-Logo-1

Team Amprion strives toward one mission

To End Alzheimer's and Parkinson's.

Alzheimer’s and Parkinson’s - A Global Health Crisis

Every 33 seconds, one American will be diagnosed with Alzheimer’s by 2050, adding to the millions of patients that, as of yet, have no cure.

Today, 5 million people in the US are diagnosed with Alzheimer’s and 1 million with Parkinson’s. These numbers are expected to triple by 2050.

Despite decades of drug development, clinical trials, and whopping spending of over US$100 billion in the US alone, there’s no cure in sight for Alzheimer’s and Parkinson’s.

Play Video

Why has it been so challenging to find treatments for neurodegenerative diseases?

Because accurate and early diagnosis has been impossible. Until now…

You Can Help!

Be a Part of Big Brain Research

Every Alzheimer’s or Parkinson’s patient is unique. To treat each person properly, we need personalized medicine.

To develop treatments, we must solve an age-old problem—diagnosing Parkinson’s or Alzheimer’s EARLY— decades before any symptoms.

Your test results speed drug development for Alzheimer’s and Parkinson’s.

Suppose you have a family history of loved ones affected by Alzheimer’s, Parkinson’s, or has suffered brain injuries earlier in life. In that case, early testing puts you in control to change the disease’s course to slow or stop the progression.

Join the race for a cure. Get tested early.

Alzheimer’s Test

For people who have a family history of Alzheimer’s, getting an early diagnosis is positively life-changing. According to the Alzheimer’s Association, delaying the onset of Alzheimer’s symptoms by just five years could reduce the number of people with an active disease by 42%.

Parkinson’s Test

For people 60 and above with a genetic predisposition to Parkinson’s, each decade of aging increases PD’s risk drastically. Getting tested early means jumpstarting to slow or stop the decline. The key is to take control of PD at the earliest stage.

Why Early Detection

To treat a disease, we must know the condition exists. The earlier, the better. Diagnosing Alzheimer’s and Parkinson’s at the early stages puts you in control to course-correct the disease. Build a support system of doctors, families, and caretakers. The goal is to empower medical science to race for a cure.

How It Works

Our Prion Detection Science™ measures the particular prion biomarker driving Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. We track the Prions during development stages in the brain—decades before symptoms.

amprion - hero - Alzheimer's page

Alzheimer's Test

For people who have a family history of Alzheimer’s, getting an early diagnosis is positively life-changing.

According to the Alzheimer’s Association, delaying the onset of Alzheimer’s symptoms by just five years could reduce the number of people with an active disease by 42%.

parkinson's early trigger

Parkinson’s Test

For people 60 and above with a genetic predisposition to Parkinson’s, each decade of aging increases PD’s risk drastically.

Getting tested early means jumpstarting to slow or stop the decline. The key is to take control of PD at the earliest stage.

A grandpa with his grandson, happy about Alzheimer's disease research

Why Early Detection

To treat a disease, we must know the condition exists. The earlier, the better. Diagnosing Alzheimer’s and Parkinson’s at the early stages puts you in control to course-correct the disease.

Build a support system of doctors, families, and caretakers. The goal is to empower medical science to race for a cure.

amprion science

How It Works

Our Prion Detection Science™ measures the particular prion biomarker driving Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.

We track the Prions during development stages in the brain—decades before symptoms.

Science is powerful. I want to change the world through science.
Claudio Author
Claudio Soto
CoFounder & Chief Scientific Officer